For the twelve months ended Sep 30, 2026, Royalty Pharma plc reported $2.62B of revenue and $672.45M of net income.
RPRX revenue was $690.10M in fiscal Q3 2026 (ended Sep 30, 2026), up 13.3% from a year earlier and up 2.4% from the prior quarter. For the full fiscal 2025 it was $2.38B, up 5.1% from fiscal 2024. Compound annual growth was +2.3% over 5 years. It rose in 5 of the last 7 fiscal years. Fiscal 2025 is the highest of the 8 fiscal years on file.
RPRX net income was $144.68M in fiscal Q3 2026 (ended Sep 30, 2026), down 49.1% from a year earlier and up 709.0% from the prior quarter. For the full fiscal 2025 it was $770.95M, down 10.2% from fiscal 2024. Compound annual growth was -4.6% over 5 years. It rose in 2 of the last 7 fiscal years.
RPRX diluted EPS was $0.32 in fiscal Q3 2026 (ended Sep 30, 2026), down 51.5% from a year earlier and up 700.0% from the prior quarter. For the full fiscal 2025 it was $1.78, down 6.8% from fiscal 2024. Compound annual growth was +6.2% over 5 years.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B | $1.81B | $1.79B |
| Research and development | $452.00M | $2.00M | $52.00M | $177.11M | $200.08M | $26.29M | $83.04M | $392.61M |
| Selling, general and admin | $573.48M | $236.67M | $249.75M | $227.30M | $182.83M | $181.72M | $103.44M | $61.91M |
| Operating income | $1.56B | $1.29B | $1.49B | $307.06M | $1.43B | $1.60B | $2.62B | $1.36B |
| Interest expense | $307.66M | $225.51M | $187.19M | $187.96M | $166.14M | $157.06M | $268.57M | $279.96M |
| Pre-tax income | $1.32B | $1.33B | $1.70B | $230.06M | $1.24B | $1.70B | $2.46B | $1.52B |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $770.95M | $858.98M | $1.13B | $42.83M | $619.73M | $975.04M | $2.35B | $1.38B |
| EPS, basic | $1.79 | $1.92 | $2.54 | $0.10 | $1.49 | $1.32 | - | - |
| EPS, diluted | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 | - | - |
| Diluted shares | 564.5M | 594.1M | 602.9M | 438.0M | 414.8M | 375.5M | - | - |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $618.70M | $929.03M | $477.01M | $1.71B | $1.54B | $1.01B | $246.20M | $1.92B |
| Current assets | $1.53B | $1.80B | $1.27B | $2.55B | $2.88B | $2.70B | $832.07M | - |
| Goodwill | $924.63M | $0 | - | - | - | - | - | - |
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B | $16.02B | $12.45B | - |
| Current liabilities | $636.21M | $1.25B | $161.38M | $1.17B | $171.25M | $307.89M | $333.42M | - |
| Short-term debt | $380.00M | $997.77M | $0 | $997.51M | $0 | $0 | $281.98M | - |
| Long-term debt | $8.57B | $6.61B | $6.14B | $6.12B | $7.10B | $5.82B | $5.96B | - |
| Total debt | $8.95B | $7.61B | $6.14B | $7.12B | $7.10B | $5.82B | $6.24B | - |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B | $6.12B | $6.31B | - |
| Shareholders' equity | $9.71B | $10.34B | $10.08B | $9.53B | $10.25B | $9.90B | $6.14B | $4.55B |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B | $2.03B | $1.67B | $1.62B |
| Investing cash flow | -$1.61B | -$2.68B | -$2.07B | -$1.03B | -$1.87B | -$2.76B | -$2.15B | $303.42M |
| Financing cash flow | -$1.19B | $361.14M | -$2.15B | -$944.86M | $385.11M | $1.49B | -$1.19B | -$1.38B |
| Share repurchases | $1.23B | $229.65M | $304.76M | $0 | $0 | $0 | $4.27M | $0 |
| Stock-based compensation | $289.89M | $2.34M | $2.36M | $2.17M | $2.44M | $5.43M | $0 | $0 |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 5.1% | -3.9% | 5.2% | -2.3% | 7.9% | 17.0% | 1.1% | - |
| Net income growth, YoY | -10.2% | -24.3% | 2549.5% | -93.1% | -36.4% | -58.5% | 70.5% | - |
| EPS growth, YoY | -6.8% | -24.5% | 2430.0% | -93.3% | 12.9% | - | - | - |
| Operating margin | 65.6% | 57.1% | 63.4% | 13.7% | 62.5% | 75.2% | 144.6% | 76.0% |
| Net margin | 32.4% | 37.9% | 48.2% | 1.9% | 27.1% | 45.9% | 129.4% | 76.8% |
| Return on equity | 7.9% | 8.3% | 11.3% | 0.4% | 6.0% | 9.9% | 38.2% | 30.3% |
| Return on assets | 3.9% | 4.7% | 6.9% | 0.3% | 3.5% | 6.1% | 18.9% | - |
| Current ratio | 2.40 | 1.44 | 7.90 | 2.19 | 16.81 | 8.76 | 2.50 | - |
| Debt to equity | 0.92 | 0.74 | 0.61 | 0.75 | 0.69 | 0.59 | 1.02 | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $690.10M | $674.14M | $630.58M | $621.99M | $609.29M | $578.66M | $568.25M | $593.64M | $564.69M | $537.27M | $567.98M | $596.07M |
| Research and development | $63.16M | $97.85M | $39.79M | $50.50M | $50.50M | $300.50M | $50.50M | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K |
| Selling, general and admin | $150.10M | $161.89M | $159.49M | $164.27M | $118.73M | $179.77M | $110.70M | $67.59M | $56.72M | $54.71M | $57.65M | $59.19M |
| Operating income | $410.84M | $133.12M | $563.04M | $388.38M | $427.16M | $209.80M | $534.18M | $361.51M | $735.07M | $269.63M | -$73.77M | $612.90M |
| Interest expense | $90.49M | $93.62M | $93.72M | $94.17M | $79.56M | $68.67M | $65.26M | $65.76M | $66.51M | $49.01M | $44.23M | $47.26M |
| Pre-tax income | $266.64M | $81.49M | $468.26M | $356.91M | $440.21M | $92.64M | $434.43M | $334.35M | $806.36M | $194.38M | -$4.27M | $717.59M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $144.68M | $17.88M | $294.69M | $215.21M | $284.22M | $32.18M | $239.35M | $208.21M | $543.99M | $102.00M | $4.78M | $494.34M |
| EPS, basic | $0.32 | $0.04 | $0.67 | $0.50 | $0.66 | $0.08 | $0.55 | $0.46 | $1.22 | $0.23 | $0.01 | $1.11 |
| EPS, diluted | $0.32 | $0.04 | $0.67 | $0.50 | $0.66 | $0.07 | $0.55 | $0.46 | $1.21 | $0.23 | $0.01 | $1.11 |
| Diluted shares | 557.0M | 556.9M | 556.8M | - | 559.6M | 562.3M | 578.1M | - | 592.7M | 596.9M | 597.5M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $513.66M | $811.99M | $586.39M | $618.70M | $938.94M | $631.91M | $1.09B | $929.03M | $950.05M | $1.76B | $843.00M | $477.01M |
| Current assets | $1.53B | $1.76B | $1.43B | $1.53B | $1.85B | $1.52B | $1.84B | $1.80B | $1.79B | $2.58B | $1.56B | $1.27B |
| Goodwill | $923.53M | $923.53M | $924.63M | $924.63M | $924.63M | $924.63M | - | $0 | - | - | - | - |
| Total assets | $19.46B | $19.82B | $19.82B | $19.62B | $19.35B | $18.32B | $17.61B | $18.22B | $18.04B | $17.66B | $16.13B | $16.38B |
| Current liabilities | $1.18B | $630.93M | $535.68M | $636.21M | $530.80M | $1.21B | $1.18B | $1.25B | $1.17B | $275.70M | $124.57M | $161.38M |
| Short-term debt | $996.97M | $380.00M | $380.00M | $380.00M | $380.00M | $999.44M | $998.61M | $997.77M | $996.94M | $0 | $0 | $0 |
| Long-term debt | $7.59B | $8.58B | $8.58B | $8.57B | $8.57B | $7.00B | $6.62B | $6.61B | $6.61B | $7.60B | $6.14B | $6.14B |
| Total debt | $8.59B | $8.96B | $8.96B | $8.95B | $8.95B | $8.00B | $7.62B | $7.61B | $7.61B | $7.60B | $6.14B | $6.14B |
| Total liabilities | $9.67B | $10.03B | $9.88B | $9.91B | $9.73B | $8.82B | $7.82B | $7.88B | $7.78B | $7.90B | $6.27B | $6.30B |
| Shareholders' equity | $9.80B | $9.79B | $9.94B | $9.71B | $9.61B | $9.49B | $9.78B | $10.34B | $10.26B | $9.75B | $9.86B | $10.08B |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $686.08M | $728.46M | $718.23M | $827.15M | $702.62M | $363.98M | $596.08M | $742.52M | $703.61M | $658.21M | $664.64M | $772.63M |
| Investing cash flow | -$285.66M | -$229.72M | -$477.87M | -$847.80M | -$958.31M | -$311.98M | $503.92M | -$505.59M | -$1.19B | -$893.18M | -$86.65M | -$1.00B |
| Financing cash flow | -$698.74M | -$273.15M | -$272.67M | -$299.60M | $562.74M | -$507.81M | -$941.30M | -$257.96M | -$325.50M | $1.16B | -$212.00M | -$231.89M |
| Share repurchases | $86.34M | $44.64M | $50.10M | $80.54M | $146.49M | $291.57M | $708.78M | $52.61M | $97.05M | $80.00M | $0 | $30.20M |
| Stock-based compensation | $104.88M | $107.07M | $121.99M | $125.77M | $72.84M | $90.77M | $515.0K | $525.0K | $526.0K | $681.0K | $612.0K | $617.0K |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 13.3% | 16.5% | 11.0% | 4.8% | 7.9% | 7.7% | 0.0% | -0.4% | 5.3% | -0.2% | -17.0% | 5.4% |
| Net income growth, YoY | -49.1% | -44.4% | 23.1% | 3.4% | -47.8% | -68.5% | 4909.4% | -57.9% | 654.3% | -55.2% | -98.6% | - |
| EPS growth, YoY | -51.5% | -42.9% | 21.8% | 8.7% | -45.5% | -69.6% | 5400.0% | -58.6% | 656.3% | -54.0% | -98.7% | - |
| Operating margin | 59.5% | 19.7% | 89.3% | 62.4% | 70.1% | 36.3% | 94.0% | 60.9% | 130.2% | 50.2% | -13.0% | 102.8% |
| Net margin | 21.0% | 2.7% | 46.7% | 34.6% | 46.6% | 5.6% | 42.1% | 35.1% | 96.3% | 19.0% | 0.8% | 82.9% |
| Current ratio | 1.29 | 2.80 | 2.66 | 2.40 | 3.48 | 1.26 | 1.56 | 1.44 | 1.54 | 9.35 | 12.52 | 7.90 |
| Debt to equity | 0.88 | 0.92 | 0.90 | 0.92 | 0.93 | 0.84 | 0.78 | 0.74 | 0.74 | 0.78 | 0.62 | 0.61 |
Source: XBRL data Royalty Pharma plc files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RPRX | $2.62B | +11.4% | $672.45M | 25.7% | $39.45B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |